Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

Forensic investigation at UFS Computer Services division in final stage of finalisation
2007-02-01

Statement by prof Niel Viljoen, Chief Director: Operations  
 
The case in which possible irregularities were investigated at the University of the Free State’s (UFS) Computer Services Division at the end of 2005, and which led to two Deputy Directors’ compulsory leave pending an investigation, is making good progress and is in the final stage of finalisation.
 
One of the Deputy Directors resigned unconditionally a day before his disciplinary hearing was to take place. He is one of two staff members who were placed on compulsory leave after an internal investigation ordered by the UFS management indicated possible irregularities in the division.
 
“As a result of the extent of the case and the involvement of more than one local business, the investigation had a long course,” said Prof Viljoen.
 
“The Deputy Director who resigned would have appeared before a disciplinary committee with Judge Joos Hefer as chairperson on charges of misconduct, involving more than R500 000,” said Prof Viljoen.
 
“We are going ahead with the process of criminal prosecution against this person and a docket was opened at the commerce branch of the South African Police Services (SAPS).  A civil action to recover damages from him was started,” Prof Viljoen said.
 
With a couple of exceptions, the internal disciplinary process of the other persons involved in the case is also finalised. “The disciplinary hearing of the Deputy Director, who is still in the service of the UFS’s Computer Services division, is scheduled for May 2007. This person is still on compulsory leave,” Prof Viljoen said.
 
“To demonstrate our commitment to the enhancement of honest work ethics and to give to personnel and students a mechanism to bring any unethical business practices to the attention of the UFS management, a fraud hotline was installed last year. The hotline is operated 24 hours a day for 365 days of the year by KPMG,” Prof Viljoen said.
 
Prof Viljoen thanked everyone who was involved in the investigation for their cooperation. This includes staff as well as people from outside the UFS.  “We are committed to transparent corporate management. Any possible irregularities will be investigated and if staff or students are found guilty of any irregular behaviour, strict actions would be taken against these persons,” Prof Viljoen said.
 
Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl@mail.ufs.ac.za
2 February 2007
 

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept